Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glivec and CML: a lucky date.

G Saglio1, D Cilloni, F Rancati

  • 1Department of Clinical and Biological Sciences, University of Turin, Hospital S. Luigi Gonzaga, Obassano, Torino, Italy. giuseppe.saglio@unito.it

Journal of Biological Regulators and Homeostatic Agents
|March 3, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Choice of Frontline Tyrosine-Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A "Campus CML" Study.

European journal of haematology·2024
Same author

Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study.

Frontiers in pharmacology·2023
Same author

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

Leukemia·2020
Same author

A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.

Leukemia·2017
Same author

Altered Erythropoiesis in Mouse Models of Type 3 Hemochromatosis.

BioMed research international·2017
Same author

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.

Leukemia·2017
Same journal

Identification of circRNA-mediated competing endogenous RNA network in the development of bladder urothelial carcinoma.

Journal of biological regulators and homeostatic agents·2021
Same journal

Dimethyl fumarate attenuates lipopolysaccharide-induced acute lung injury by inhibiting inflammation and oxidative stress.

Journal of biological regulators and homeostatic agents·2021
Same journal

Expression of NLR and IL-1β and their predictive efficacy value in acute myocardial infarction patients treated with aspirin combined with clopidogrel.

Journal of biological regulators and homeostatic agents·2021
Same journal

CircRNA (circ_0008057) promotes uremic serum-mediated proliferation and migration of vascular smooth muscle cells via miR-370/PLk1 signaling pathway.

Journal of biological regulators and homeostatic agents·2021
Same journal

Overexpression of miR-150-5p alleviates lipopolysaccharide-induced A549 cell injury in type II alveolar epithelial cells by inhibiting the FSTL1 signaling pathway.

Journal of biological regulators and homeostatic agents·2021
Same journal

Efficacy of early oral and perioral physiotherapy on feeding autonomy in preterm infants: results of randomized controlled trials.

Journal of biological regulators and homeostatic agents·2021
See all related articles

Chronic Myeloid Leukemia (CML) is a model for understanding leukemia pathogenesis. The development of imatinib, a tyrosine kinase inhibitor, has revolutionized CML treatment and pioneered targeted cancer therapies.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Chronic Myeloid Leukemia (CML) is linked to the Philadelphia chromosome (Ph) and the BCR-ABL fusion gene.
  • The BCR-ABL gene produces a constitutively active tyrosine kinase (TK), driving CML pathogenesis.

Purpose of the Study:

  • To highlight CML as a model for leukemia research.
  • To discuss the impact of targeted therapy in CML treatment.

Main Methods:

  • Review of CML molecular pathogenesis.
  • Analysis of imatinib's clinical introduction and impact.

Main Results:

  • CML pathogenesis is understood through the BCR-ABL tyrosine kinase.
  • Imatinib significantly improved CML treatment outcomes.

Related Experiment Videos

Conclusions:

  • CML serves as a paradigm for understanding and treating leukemias.
  • Imatinib's success heralded a new era of molecularly targeted cancer therapy.